Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists
Authors
Keywords
-
Journal
DRUG SAFETY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-04-11
DOI
10.1007/s40264-019-00812-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio
- (2018) Masayuki Kaneko et al. ANNALS OF PHARMACOTHERAPY
- Patients with Obesity Caused by Melanocortin-4 Receptor Mutations Can Be Treated with a Glucagon-like Peptide-1 Receptor Agonist
- (2018) Eva W. Iepsen et al. Cell Metabolism
- Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity
- (2018) Christina C. Nexøe-Larsen et al. DIABETES OBESITY & METABOLISM
- Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss
- (2018) Jens Juul Holst et al. Surgery for Obesity and Related Diseases
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis
- (2018) M Angelyn Bethel et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
- (2018) Erin A. Bohula et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cracking the combination: Gut hormones for the treatment of obesity and diabetes
- (2018) Kleopatra Alexiadou et al. JOURNAL OF NEUROENDOCRINOLOGY
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
- (2017) Melanie Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
- (2017) Carel W le Roux et al. LANCET
- Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
- (2017) Giovanna Muscogiuri et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
- (2017) Christopher Sorli et al. Lancet Diabetes & Endocrinology
- Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review
- (2016) Igho J. Onakpoya et al. BMC Medicine
- Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning
- (2016) Marina V. Basalay et al. CARDIOVASCULAR RESEARCH
- Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients
- (2016) Mark M. Smits et al. DIABETES OBESITY & METABOLISM
- Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes
- (2016) P. Mensberg et al. DIABETES OBESITY & METABOLISM
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
- (2016) W. Timothy Garvey et al. Endocrine Practice
- Weight management in obesity - past and present
- (2016) D. Haslam INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
- (2016) A Blackman et al. INTERNATIONAL JOURNAL OF OBESITY
- Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors
- (2016) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events
- (2016) Rohan Khera et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effect of bariatric surgery on gastrointestinal and pancreatic peptide hormones
- (2016) Claire L Meek et al. PEPTIDES
- Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus
- (2016) Lotte Bjerre Knudsen et al. Journal of Diabetes Investigation
- Probability of an Obese Person Attaining Normal Body Weight: Cohort Study Using Electronic Health Records
- (2015) Alison Fildes et al. AMERICAN JOURNAL OF PUBLIC HEALTH
- Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes
- (2015) Cristina Hernández et al. DIABETES
- A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes
- (2015) Michael A. Nauck et al. DIABETES CARE
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
- (2015) Jesper Lau et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss
- (2014) E W Iepsen et al. INTERNATIONAL JOURNAL OF OBESITY
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
- (2014) Anna Secher et al. JOURNAL OF CLINICAL INVESTIGATION
- Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
- (2014) Amy G. Egan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
- (2014) Gian Paolo Fadini et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications
- (2013) S. Madsbad DIABETES OBESITY & METABOLISM
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
- (2013) J van Can et al. INTERNATIONAL JOURNAL OF OBESITY
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
- (2013) Michael D. Jensen et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Emerging combinatorial hormone therapies for the treatment of obesity and T2DM
- (2013) Sharon A. Sadry et al. Nature Reviews Endocrinology
- Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
- (2013) Caroline M. Apovian et al. Obesity
- Eight-year weight losses with an intensive lifestyle intervention: The look AHEAD study
- (2013) Obesity
- Interdisciplinary European Guidelines on Metabolic and Bariatric Surgery
- (2013) M. Fried et al. OBESITY SURGERY
- Alterations in energy balance following exenatide administration
- (2012) David P. Bradley et al. Applied Physiology Nutrition and Metabolism
- Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders
- (2012) Isidro Salcedo et al. BRITISH JOURNAL OF PHARMACOLOGY
- Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight
- (2012) J. Jelsing et al. DIABETES OBESITY & METABOLISM
- GLP-1 Receptor Agonists and the Thyroid: C-Cell Effects in Mice Are Mediated via the GLP-1 Receptor and not Associated with RET Activation
- (2012) Lars Wichmann Madsen et al. ENDOCRINOLOGY
- Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
- (2011) R. R. Wing et al. DIABETES CARE
- Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4
- (2011) Scott E. Kanoski et al. ENDOCRINOLOGY
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential
- (2011) S. S. Torekov et al. Obesity Reviews
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
- (2010) W. Philip T. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Review of Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy—Report of the ISPOR Risk–Benefit Management Working Group
- (2010) Jeff J. Guo et al. VALUE IN HEALTH
- The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis
- (2009) Daphne P Guh et al. BMC PUBLIC HEALTH
- Annual Medical Spending Attributable To Obesity: Payer-And Service-Specific Estimates
- (2009) Eric A. Finkelstein et al. HEALTH AFFAIRS
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- The Medical Risks of Obesity
- (2009) Xavier Pi-Sunyer POSTGRADUATE MEDICINE
- Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety
- (2008) Diana L. Williams et al. ENDOCRINOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started